The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias
This activity contains:
- CME/CNE-Certified Live Webinars
The goal of this activity is to provide healthcare professionals with the latest information regarding the use of CAR T-cell therapy in the management of relapsed and refractory lymphomas and leukemias.
The treatment of relapsed or refractory leukemias and lymphomas continues to be challenging, often characterized by limited therapeutic options and poor outcomes. Effective new therapies are needed for these patients.
Chimeric antigen receptor (CAR) T-cell therapy represents a radical departure from other therapies by simultaneously being cell therapy, gene therapy, and immunotherapy. This therapy has shown considerable promise in the treatment of malignancies, especially relapsed or refractory B-cell malignancies. CAR T-cell therapies that target CD019, a protein on the cell surface of the B-cell malignancy, have induced high complete response rates in patients with B-cell leukemia or lymphoma who have very limited treatment options. Efficacy has been demonstrated in patients with relapsed or refractory acute lymphocytic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.
This activity will provide an overview on CAR T-cell therapy, including an assessment of the latest efficacy and safety data of emerging agents and a discussion on how these agents may fit into the treatment paradigm for relapsed or refractory leukemias and lymphomas.
Overview of refractory and relapsed lymphoma and leukemia
Chimeric antigen receptor T-cell therapy
Mechanism of action
Efficacy and safety of emerging agents
Diagnosing, preventing, and managing toxicities
Integrating CAR T-cell therapy into practice
This activity is intended for hematologists-oncologists, advanced practice registered nurses, nurses, and other healthcare professionals who treat and manage refractory and relapsed lymphomas and leukemias.
At the conclusion of this activity, participants should be better able to:
- Identify key features of the mechanism of action of CAR T-cell therapies in the setting of lymphomas and leukemias
- Devise management strategies that incorporate the efficacy and safety data for CAR T-cell therapies for relapsed or refractory lymphomas and leukemias
- Integrate CAR T-cell therapy into the overall treatment plan of a patient with relapsed or refractory lymphomas and leukemias based on current evidence
- Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
Marco L. Davila, MD, PhD
Kevin J. Curran, MD
Fredrick L. Locke, MD
Jae Park, MD
Continuing Medical Education
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Kevin J. Curran, MD||Kevin J. Curran, MD, reported a financial interest/relationship or affiliation in the form of consultant: Guidepoint Global Advisors, Schlesinger Associates.|
|Marco L. Davila, MD, PhD||Marco L. Davila, MD, PhD, reported a financial interest/relationship or affiliation in the form of received income in any amount from: Kite Pharma, GBMG, Precision Bioscience, Servier; and ownership interest in Adaptive Biotechnologies.|
|Fredrick L. Locke, MD||Frederick Locke, MD, reported a financial interest/relationship or affiliation in the form of Advisory board: Kite Pharmaceuticals and Contracted research Bristol-Myers Squibb Company.|
|Jae Park, MD||Jae Park, MD, reported a financial interest/relationship or affiliation in the form of received research grant from: Genentech, and Juno Therapeutics.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS, Ronald Viggiani, MD, Jocelyn Timko, and Marilyn Haas, PhD, RN, CNS, ANP-BC state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by an educational grant from Kite Pharma, Inc.
There is no fee for this educational activity.
This activity is provided by:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Attendance